Press releases – BioArctic

BioArctic’s partner Eisai publishes statement relating to article on lecanemab in Scienceinsider

December 23, 2022 - Other press release

Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a statement regarding an article on the safety of lecanemab ...

BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China

December 23, 2022 - Other press release

Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated submission of data for Biologics License ...

Number of shares and votes in BioArctic AB (publ) as of November 30, 2022

November 30, 2022 - Regulatory press release

Stockholm, November 30, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during November issued 71, 586 B shares for delivery ...

Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease published in the New England Journal of Medicine

November 30, 2022 - Regulatory press release

Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...

BioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference

November 30, 2022 - Regulatory press release

Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...

Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference

November 21, 2022 - Other press release

Stockholm, November 21, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 ...

BioArctic expands portfolio with alpha-synuclein Brain Transporter project

November 17, 2022 - Other press release

Stockholm, November 17, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company is expanding its alpha-synuclein project portfolio. The new project, ...

BioArctic receives new patent in the US for blood-brain barrier transport technology

November 14, 2022 - Other press release

Stockholm, November 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted BioArctic a ...

BioArctic develops new treatment for Gaucher’s disease

November 8, 2022 - Other press release

Stockholm, November 8, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has initiated a new project focused on enzyme replacement ...

BioArctic’s founders intend to divest minor part of their shareholding

October 25, 2022 - Regulatory press release

Stockholm, October 25, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two founders and main shareholders, Lars Lannfelt ...

Interim Report for the period July – September 2022

October 20, 2022 - Regulatory press release

Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 Lecanemab showed positive results in the pivotal Phase ...

BioArctic presents Nomination Committee

October 18, 2022 - Regulatory press release

Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment ...

Invitation to presentation of BioArctic’s third quarter report for July – September 2022 on October 20 at 9.30 a.m. CET

October 14, 2022 - Other press release

Stockholm, Sweden, October 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2022 on Thursday, ...

Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance

September 28, 2022 - Regulatory press release

Stockholm, September 28, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory ...

Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC)

August 5, 2022 - Other press release

Stockholm, August 5, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril ...

Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

July 26, 2022 - Other press release

Stockholm, July 26, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) ...

Interim Report for the period April – June 2022

July 12, 2022 - Regulatory press release

FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...

The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer’s disease under the accelerated approval pathway

July 6, 2022 - Regulatory press release

Stockholm, July 6, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted ...

Invitation to presentation of BioArctic’s second quarter report for April – June 2022 on July 12 at 9.30 a.m. CET

July 5, 2022 - Other press release

Stockholm, Sweden, July 5, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report for April – June 2022 on Tuesday, July ...

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

May 10, 2022 - Regulatory press release

Stockholm, May 10, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. ...

BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease

May 6, 2022 - Other press release

Stockholm, May 6, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new ...

Report from annual general meeting in BioArctic AB (publ)

May 5, 2022 - Regulatory press release

Stockholm, Sweden, May 5, 2022 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to Covid-19, the Annual General Meeting ...

Interim Report for the period January – March 2022

April 28, 2022 - Regulatory press release

Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years

April 27, 2022 - Other press release

Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...

Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at 9.30 a.m. CET

April 20, 2022 - Other press release

Stockholm, Sweden, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s First Quarter Report for January – March 2022 on ...

AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio

April 20, 2022 - Regulatory press release

Stockholm, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company’s partner AbbVie has decided to terminate its collaboration with ...

Notice of Annual General Meeting in BioArctic AB (Publ)

April 6, 2022 - Regulatory press release

The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 5 May 2022

BioArctic publishes the Annual Report for 2021

March 31, 2022 - Regulatory press release

Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...

BioArctic and Eisai presented latest data regarding lecanemab at the AD/PD[TM] 2022 conference

March 21, 2022 - Other press release

Stockholm, March 21, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta ...

Latest lecanemab data to be presented at the AD/PD™ congress

March 11, 2022 - Other press release

Stockholm, March 11, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...

The Nomination Committee’s proposal for the election of board members in BioArctic AB

March 9, 2022 - Regulatory press release

Stockholm March 9, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

March 4, 2022 - Regulatory press release

Stockholm, March 4, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) ...

Proud partner of: